Voyager Historical Balance Sheet

VYGR Stock

USD 3.74 0.10 2.75%

Trend analysis of Voyager Therapeutics balance sheet accounts such as Total Assets of 229.7 M, Short Long Term Debt Total of 30.6 M, Other Current Liabilities of 10.8 M or Total Current Liabilities of 39.6 M provides information on Voyager Therapeutics' total assets, liabilities, and equity, which is the actual value of Voyager Therapeutics to its prevalent stockholders. By breaking down trends over time using Voyager Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Voyager Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Voyager Therapeutics is a good buy for the upcoming year.

Voyager Therapeutics Inventory

1.21

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Voyager Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Voyager Stock, please use our How to Invest in Voyager Therapeutics guide.

About Voyager Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Voyager Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Voyager Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Voyager Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Voyager currently owns. An asset can also be divided into two categories, current and non-current.

Voyager Therapeutics Balance Sheet Chart

At this time, Voyager Therapeutics' Other Current Assets are relatively stable compared to the past year. As of 03/27/2025, Long Term Investments is likely to grow to about 69 M, while Short and Long Term Debt Total is likely to drop slightly above 30.6 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Voyager Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Voyager Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Voyager Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Voyager Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Voyager Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Voyager Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Voyager Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Voyager Stock, please use our How to Invest in Voyager Therapeutics guide.At this time, Voyager Therapeutics' Other Current Assets are relatively stable compared to the past year. As of 03/27/2025, Long Term Investments is likely to grow to about 69 M, while Short and Long Term Debt Total is likely to drop slightly above 30.6 M.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	23.1M	20.3M	43.7M	30.6M
Total Assets	159.4M	351.3M	393.1M	229.7M

Short Long Term Debt Total Total Assets

Voyager Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Total Current Assets	Short Term Debt	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Common Stock Total Equity	Short Term Investments	Other Current Assets	Other Stockholder Equity	Deferred Long Term Liab
Total Assets		0.81	0.91	0.78	0.82	-0.68	-0.75	0.52	0.74	0.71	0.41	0.33	0.98	0.85	0.69	0.79	0.99	0.3	0.39	0.71	0.72	0.91	-0.01	0.63	0.83	0.2
Short Long Term Debt Total	0.81		0.74	0.54	0.66	-0.77	-0.72	0.21	0.79	0.65	0.31	0.65	0.83	0.75	0.6	0.65	0.77	0.36	0.38	0.87	0.73	0.89	-0.37	0.54	0.73	0.36
Other Current Liab	0.91	0.74		0.81	0.65	-0.72	-0.81	0.52	0.79	0.61	0.27	0.5	0.87	0.86	0.82	0.9	0.91	0.2	0.53	0.6	0.79	0.88	-0.11	0.57	0.87	0.21
Total Current Liabilities	0.78	0.54	0.81		0.5	-0.81	-0.88	0.6	0.83	0.56	0.23	0.36	0.72	0.79	0.64	0.85	0.76	0.12	0.35	0.4	0.73	0.82	-0.31	0.56	0.82	-0.07
Total Stockholder Equity	0.82	0.66	0.65	0.5		-0.39	-0.59	0.53	0.51	0.84	0.73	-0.02	0.79	0.69	0.31	0.42	0.8	0.43	-0.03	0.65	0.52	0.73	0.0	0.77	0.67	0.22
Net Debt	-0.68	-0.77	-0.72	-0.81	-0.39		0.85	-0.16	-0.93	-0.42	0.02	-0.75	-0.67	-0.75	-0.58	-0.73	-0.67	-0.06	-0.33	-0.66	-0.74	-0.88	0.68	-0.45	-0.77	-0.2
Retained Earnings	-0.75	-0.72	-0.81	-0.88	-0.59	0.85		-0.57	-0.92	-0.73	-0.42	-0.49	-0.69	-0.9	-0.61	-0.78	-0.7	-0.32	-0.26	-0.49	-0.85	-0.9	0.54	-0.77	-0.93	-0.05
Accounts Payable	0.52	0.21	0.52	0.6	0.53	-0.16	-0.57		0.35	0.71	0.74	-0.13	0.47	0.53	0.46	0.56	0.47	0.38	0.23	0.07	0.43	0.42	0.17	0.64	0.54	-0.14
Cash	0.74	0.79	0.79	0.83	0.51	-0.93	-0.92	0.35		0.65	0.21	0.67	0.67	0.83	0.59	0.75	0.68	0.3	0.24	0.6	0.93	0.88	-0.62	0.68	0.86	0.04
Non Current Assets Total	0.71	0.65	0.61	0.56	0.84	-0.42	-0.73	0.71	0.65		0.85	0.07	0.64	0.7	0.39	0.5	0.62	0.61	0.0	0.48	0.73	0.69	-0.19	0.92	0.71	-0.08
Non Currrent Assets Other	0.41	0.31	0.27	0.23	0.73	0.02	-0.42	0.74	0.21	0.85		-0.33	0.36	0.45	0.07	0.15	0.33	0.61	-0.2	0.15	0.33	0.35	0.08	0.77	0.44	-0.04
Other Assets	0.33	0.65	0.5	0.36	-0.02	-0.75	-0.49	-0.13	0.67	0.07	-0.33		0.37	0.43	0.55	0.54	0.33	-0.06	0.5	0.59	0.56	0.54	-0.58	0.08	0.43	0.41
Cash And Short Term Investments	0.98	0.83	0.87	0.72	0.79	-0.67	-0.69	0.47	0.67	0.64	0.36	0.37		0.76	0.72	0.79	0.98	0.2	0.49	0.8	0.61	0.89	0.01	0.51	0.74	0.28
Common Stock Shares Outstanding	0.85	0.75	0.86	0.79	0.69	-0.75	-0.9	0.53	0.83	0.7	0.45	0.43	0.76		0.54	0.7	0.8	0.48	0.21	0.49	0.81	0.91	-0.31	0.75	0.98	0.22
Non Current Liabilities Total	0.69	0.6	0.82	0.64	0.31	-0.58	-0.61	0.46	0.59	0.39	0.07	0.55	0.72	0.54		0.95	0.71	-0.01	0.89	0.49	0.58	0.63	0.0	0.26	0.54	0.06
Total Liab	0.79	0.65	0.9	0.85	0.42	-0.73	-0.78	0.56	0.75	0.5	0.15	0.54	0.79	0.7	0.95		0.8	0.05	0.75	0.51	0.7	0.77	-0.13	0.41	0.71	0.02
Total Current Assets	0.99	0.77	0.91	0.76	0.8	-0.67	-0.7	0.47	0.68	0.62	0.33	0.33	0.98	0.8	0.71	0.8		0.18	0.45	0.72	0.63	0.89	0.02	0.54	0.78	0.26
Short Term Debt	0.3	0.36	0.2	0.12	0.43	-0.06	-0.32	0.38	0.3	0.61	0.61	-0.06	0.2	0.48	-0.01	0.05	0.18		-0.24	0.06	0.44	0.25	-0.03	0.53	0.39	-0.12
Other Liab	0.39	0.38	0.53	0.35	-0.03	-0.33	-0.26	0.23	0.24	0.0	-0.2	0.5	0.49	0.21	0.89	0.75	0.45	-0.24		0.33	0.19	0.33	0.18	-0.17	0.19	0.13
Net Tangible Assets	0.71	0.87	0.6	0.4	0.65	-0.66	-0.49	0.07	0.6	0.48	0.15	0.59	0.8	0.49	0.49	0.51	0.72	0.06	0.33		0.48	0.75	-0.28	0.35	0.47	0.48
Property Plant And Equipment Net	0.72	0.73	0.79	0.73	0.52	-0.74	-0.85	0.43	0.93	0.73	0.33	0.56	0.61	0.81	0.58	0.7	0.63	0.44	0.19	0.48		0.78	-0.44	0.75	0.85	-0.07
Common Stock Total Equity	0.91	0.89	0.88	0.82	0.73	-0.88	-0.9	0.42	0.88	0.69	0.35	0.54	0.89	0.91	0.63	0.77	0.89	0.25	0.33	0.75	0.78		-0.39	0.66	0.91	0.28
Short Term Investments	-0.01	-0.37	-0.11	-0.31	0.0	0.68	0.54	0.17	-0.62	-0.19	0.08	-0.58	0.01	-0.31	0.0	-0.13	0.02	-0.03	0.18	-0.28	-0.44	-0.39		-0.32	-0.35	-0.05
Other Current Assets	0.63	0.54	0.57	0.56	0.77	-0.45	-0.77	0.64	0.68	0.92	0.77	0.08	0.51	0.75	0.26	0.41	0.54	0.53	-0.17	0.35	0.75	0.66	-0.32		0.78	-0.11
Other Stockholder Equity	0.83	0.73	0.87	0.82	0.67	-0.77	-0.93	0.54	0.86	0.71	0.44	0.43	0.74	0.98	0.54	0.71	0.78	0.39	0.19	0.47	0.85	0.91	-0.35	0.78		0.19
Deferred Long Term Liab	0.2	0.36	0.21	-0.07	0.22	-0.2	-0.05	-0.14	0.04	-0.08	-0.04	0.41	0.28	0.22	0.06	0.02	0.26	-0.12	0.13	0.48	-0.07	0.28	-0.05	-0.11	0.19

Click cells to compare fundamentals

Voyager Therapeutics Account Relationship Matchups

Voyager Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	261.6M	193.9M	159.4M	351.3M	393.1M	229.7M
Short Long Term Debt Total	47.6M	44.2M	23.1M	20.3M	43.7M	30.6M
Other Current Liab	14.2M	11.0M	7.8M	16.8M	14.2M	10.8M
Total Current Liabilities	26.8M	51.0M	72.6M	64.5M	49.8M	39.6M
Total Stockholder Equity	154.3M	95.1M	59.0M	236.3M	299.8M	314.7M
Net Debt	(56.8M)	(73.3M)	(75.8M)	(48.5M)	(27.6M)	(29.0M)
Retained Earnings	(275.9M)	(347.1M)	(393.5M)	(261.2M)	(326.2M)	(342.5M)
Accounts Payable	634K	574K	2.6M	1.6M	4.0M	4.2M
Cash	104.4M	117.4M	99.0M	68.8M	71.4M	64.2M
Non Current Assets Total	63.8M	57.2M	34.9M	31.6M	116.2M	122.1M
Non Currrent Assets Other	537K	1.8M	1.5M	(1.0)	68.6M	72.0M
Other Assets	2.3M	1.8M	1.5M	1.0	1.15	1.09
Cash And Short Term Investments	181.1M	132.5M	118.8M	230.9M	266.7M	178.1M
Common Stock Shares Outstanding	37.3M	37.7M	38.4M	44.6M	57.7M	32.5M
Liabilities And Stockholders Equity	261.6M	193.9M	159.4M	351.3M	393.1M	229.7M
Non Current Liabilities Total	80.5M	47.8M	27.7M	50.5M	43.5M	59.7M
Total Liab	107.3M	98.8M	100.3M	115.0M	93.3M	98.9M
Total Current Assets	197.8M	136.7M	124.5M	319.7M	276.8M	190.4M
Short Term Debt	4.2M	5.6M	2.8M	3.2M	7.2M	4.9M
Other Liab	148.3M	37.1M	9.2M	7.5M	8.6M	8.1M
Net Tangible Assets	99.5M	154.3M	95.1M	59.0M	67.9M	106.6M
Property Plant And Equipment Net	61.5M	55.4M	33.3M	30.0M	47.7M	31.1M
Short Term Investments	76.7M	15.1M	19.9M	162.1M	195.3M	100.0M
Other Current Assets	6.9M	3.4M	5.0M	4.4M	8.6M	9.1M
Other Stockholder Equity	430.3M	442.3M	452.7M	497.5M	626.3M	371.0M
Property Plant And Equipment Gross	25.4M	71.3M	50.5M	45.0M	63.6M	33.9M
Accumulated Other Comprehensive Income	(134K)	(138K)	(219K)	(48K)	(407K)	(427.4K)
Property Plant Equipment	46.5M	25.4M	21.9M	17.9M	20.5M	18.2M
Current Deferred Revenue	7.7M	42.1M	65.8M	42.9M	24.4M	30.9M
Net Receivables	8.0M	748K	639K	84.5M	1.5M	1.4M
Retained Earnings Total Equity	(312.6M)	(275.9M)	(347.1M)	(393.5M)	(354.2M)	(371.9M)
Capital Surpluse	412.2M	430.3M	442.3M	452.7M	520.6M	384.1M
Inventory	6.9M	1.7M	779K	1.0	1.15	1.21
Net Invested Capital	154.3M	95.1M	59.0M	236.3M	299.8M	154.6M
Net Working Capital	171.0M	85.7M	51.9M	255.2M	227.0M	179.6M

Pair Trading with Voyager Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Voyager Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Voyager Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Voyager Stock

0.76	CDIOW	Cardio Diagnostics	Pair Corr
0.74	ELVN	Enliven Therapeutics	Pair Corr

Moving against Voyager Stock

0.92	LUCD	Lucid Diagnostics	Pair Corr
0.84	WM	Waste Management	Pair Corr
0.66	GE	GE Aerospace	Pair Corr
0.46	PG	Procter Gamble	Pair Corr
0.45	PLX	Protalix Biotherapeutics	Pair Corr

The ability to find closely correlated positions to Voyager Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Voyager Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Voyager Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Voyager Therapeutics to buy it.

The correlation of Voyager Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Voyager Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Voyager Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Voyager Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Voyager Stock Analysis

When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Voyager Historical Balance Sheet

Voyager Therapeutics Inventory

1.21

About Voyager Balance Sheet Analysis

Voyager Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Voyager Therapeutics balance sheet Correlations

Voyager Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Voyager Therapeutics balance sheet Accounts

Pair Trading with Voyager Therapeutics

Moving together with Voyager Stock

Moving against Voyager Stock

Additional Tools for Voyager Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.98	Total Assets
Total Current Assets	+ 0.98	Cash And Short Term Investments
Other Stockholder Equity	+ 0.98	Common Stock Shares Outstanding
Total Liab	+ 0.95	Non Current Liabilities Total
Property Plant And Equipment Net	+ 0.93	Cash

Other Stockholder Equity	- 0.93	Retained Earnings
Cash	- 0.93	Net Debt
Cash	- 0.92	Retained Earnings
Common Stock Total Equity	- 0.9	Retained Earnings
Common Stock Shares Outstanding	- 0.9	Retained Earnings
Common Stock Total Equity	- 0.88	Net Debt